Home About us Contact
|
Home About us Contact | ||
|
|
||
Probiotic Preparation (probiotic + preparation)
Selected AbstractsORIGINAL ARTICLE: Effect of Lactobacillus fermentum and Enterococcus faecium strains on internal milieu, antioxidant status and body weight of broiler chickensJOURNAL OF ANIMAL PHYSIOLOGY AND NUTRITION, Issue 5 2010M. Capcarova Summary The aim of the present study was to evaluate the functional efficiency of two probiotic strains Lactobacillus fermentum CCM 7158 and Enterococcus faecium M 74 given to the drinking water on internal milieu, antioxidant status and body weight of broiler chickens. The experiment was conducted on hybrid Hybro (n = 180). The feeding period lasted 42 days. Experimental chickens of E1 group received a probiotic preparation in drinking water with concentration of 1 × 109 colony forming units (CFU) of L. fermentum CCM 7158 in 1 g of nutrient medium and experimental chickens of E2 group concentration of 2 × 109 CFU of E. faecium M 74 in 1 g of nutrient medium. The control group of animals received water without any additives. Triglycerides content in serum mainly with L. fermentum strain against the control group was decreased. Calcium content in both experimental groups and significantly in E. faecium group was increased. Antioxidant status in both probiotic groups was significantly increased. The content of bilirubin in group with E. faecium M 74 was significantly increased. In conclusion, addition of a microbial feed additive (L. fermentum and E. faecium) increased serum calcium and iron level, decreased triglycerides content in blood and slightly increased body weight of broiler chickens. [source] Clinical trial: a multistrain probiotic preparation significantly reduces symptoms of irritable bowel syndrome in a double-blind placebo-controlled studyALIMENTARY PHARMACOLOGY & THERAPEUTICS, Issue 1 2009E. A. WILLIAMS Summary Background, The efficacy of probiotics in alleviating the symptoms of irritable bowel syndrome (IBS) appears to be both strain- and dose-related. Aim, To investigate the effect of LAB4, a multistrain probiotic preparation on symptoms of IBS. This probiotic preparation has not previously been assessed in IBS. Methods, Fifty-two participants with IBS, as defined by the Rome II criteria, participated in this double blind, randomized, placebo-controlled study. Participants were randomized to receive either a probiotic preparation comprising two strains of Lactobacillus acidophilus CUL60 (NCIMB 30157) and CUL21 (NCIMB 30156), Bifidobacterium lactis CUL34 (NCIMB 30172) and Bifidobacterium bifidum CUL20 (NCIMB 30153) at a total of 2.5 × 1010 cfu/capsule or a placebo for 8 weeks. Participants reported their IBS symptoms using a questionnaire fortnightly during the intervention and at 2 weeks post-intervention. Results, A significantly greater improvement in the Symptom Severity Score of IBS and in scores for quality of life, days with pain and satisfaction with bowel habit was observed over the 8-week intervention period in the volunteers receiving the probiotic preparation than in the placebo group. Conclusion, LAB4 multistrain probiotic supplement may benefit subjects with IBS. [source] Probiotic supplementation affects pulmonary exacerbations in patients with cystic fibrosis: A pilot studyPEDIATRIC PULMONOLOGY, Issue 6 2010Batia Weiss MD Abstract Objective Probiotics reduce intestinal inflammation in, and Lactobacillus GG (LGG) reduces pulmonary exacerbation rate cystic fibrosis (CF) patients. We intended to determine the effect of a mixed probiotic preparation on pulmonary exacerbations and inflammatory characteristics of the sputum in CF patients. Study Design A prospective pilot study of 10 CF patients with mild,moderate lung disease and Pseudomonas aeruginosa colonization, treated with probiotics for 6 months. Pulmonary function tests (PFT's), sputum cultures with semi-quantitative bacterial analysis, and sputum neutrophil count and interleukin-8 (IL-8) levels were compared to pre-treatment and post-treatment values. The rate of pulmonary exacerbations was compared to 2 years prior to the study. Results The exacerbation rate was significantly reduced in comparison to the previous 2 years and to 6 months post-treatment (P,=,0.002). PFT's have not changed at the end of treatment and during 6 months post-treatment. No change in sputum bacteria, neutrophil count, and IL-8 levels was observed. Conclusion Probiotics reduce pulmonary exacerbations rate in patients with CF. Probiotics may have a preventive potential for pulmonary deterioration in CF patients. Pediatr Pulmonol. 2010; 45:536,540. © 2010 Wiley-Liss, Inc. [source] Binding of extracellular matrix molecules by probiotic bacteriaLETTERS IN APPLIED MICROBIOLOGY, Issue 4 2003tyriak Abstract Aims: The aim of this study was to investigate extracellular matrix (ECM) and mucin binding of selected bacterial isolates with probiotic features in comparison with commercially used probiotic bacteria. Methods and Results: ECM molecules were immobilized in microtitre plates (mucin and fetuin) or on the surface of latex beads. Porcine mucin was bound by all 13 probiotic strains tested with important inter-strain differences; however, fetuin binding was similar (weak) for all 14 strains tested. Strongly positive (three) binding of bovine fibrinogen was expressed by strains from fermented food (Lactobacillus rhamnosus GG, L. casei Shirota and L. johnsonii La1) as well as by L. casei L.c., Lactobacillus sp. 2I3 and by L. plantarum LP. The other strains expressed moderate (2) or weakly positive (1) binding of bovine fibrinogen. Strongly positive (3) binding of porcine fibronectin was observed only with two strains; however, all other strains also bound this molecule. Bovine lactoferrin was bound to a higher extent than transferrins. Significance and Impact of the Study: Some animal strains (at least L. casei L.c. and Lactobacillus sp. 2I3) are comparable with the commercially used strains with respect to their ECM binding ability. As this feature is important for probiotic bacteria to be able to colonize intestine, these strains should be considered for their wider use in fermented feed (or probiotic preparations) for animals. [source] Cow's milk allergic children can present sensitisation to probioticsACTA PAEDIATRICA, Issue 2 2009Francesca M Bruni Abstract Aim: To evaluate sensitivity to different probiotics in children with cow's milk allergy. Methods: Eighty-five patients (age range: 4 months ,12 years) presenting atopic dermatitis (AD) were enrolled. Skin prick test (SPT) responses to three different probiotics preparations (Fiorilac®, Dicoflor® and Reuterin®) were evaluated in addition to relevant food allergens. Results: Thirty-nine patients out of 85 (45.8%) had a positive skin response to prick test for cow's milk (3 with reaction <3 mm). Of the thirty-six patients with a cow's milk weal reaction >3 mm, twenty-eight (77.8%) had a skin response to Fiorilac®, four patients (11%) to Dicoflor® and four (11%) to Reuterin®. The proportion of SPT reaction to all the investigated probiotics preparations was significantly lower than cow's milk (r = 9.406; p = 0.002). A significantly higher sensitization was observed for Fiorilac® versus Dicoflor® (r = 30.916; p < 0.001) and versus Reuterin® (r = 34.133; p < 0.001). Conclusion: Probiotic use in patients with cow's milk allergy has to be limited to products that do not contain milk. This should be clearly reported in the label. In selected patients, it is advisable to perform a screening SPT with the product to evaluate its potential contamination with milk. [source] | |||||||||||||